Eli Lilly Analyst Price Targets

Eli Lilly and Co

LLYNYSE

Trade with Public

$1257.03

5.420.43%

最終更新: Oct 16, 7:54 PM

$1256.85

5.240.42%

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

決算: Q3 2026 Q3 2026のこれから木 10 29thの12 日後決算、マーケットオープン前。

Eli Lilly Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eli Lilly (LLY).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

20Buy

1Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$1248Upside to Avg. PT-0.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	RBC Capital	Trung Huynh	Maintained	Outperform	$1500
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$1410→$1440
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$1419→$1430
Sep 28, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$1400→$1500
Sep 22, 2026	TD Cowen	Steve Scala	Maintained	Buy	$1250
Sep 18, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$1273→$1284
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Reduce	$850→$940
Aug 7, 2026	Truist Securities	Robyn Karnauskas	PT Raise	Buy	$1370→$1376
Aug 6, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$1280→$1330
Aug 6, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$1350→$1410
Jul 15, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$1500→$1600
Jul 14, 2026	Bernstein	Courtney Breen	PT Raise	Outperform	$1300→$1385
Jul 13, 2026	UBS	Michael Yee	PT Raise	Buy	$1250→$1425
Jul 13, 2026	Guggenheim	Seamus Fernandez	PT Cut	Buy	$1235→$1273
Jul 10, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$1251→$1334
Jul 8, 2026	Truist Securities	Robyn Karnauskas	PT Raise	Buy	$1281→$1370
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$1344→$1347
Jul 8, 2026	RBC Capital	Trung Huynh	PT Raise	Outperform	$1250→$1500
Jul 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$1300→$1400
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$1230→$1350

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

RBC Capital analyst Trung Huynh reiterates Eli Lilly (NYSE:LLY) with a Outperform and maintains $1500 price target.

Benzinga Newsdesk

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.

Avi Kapoor

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

Cantor Fitzgerald analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1410 to $1440.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1419 to $1430.

Benzinga Newsdesk

Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone

Home Depot co-founder Ken Langone says Eli Lilly could hit $2,000 in 3 to 4 years, challenging Home Depot as his top portfolio holding.

Rishabh Mishra

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.

Vandana Singh

Eli Lilly and Co

Eli Lilly Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

ニュース

パートナーシップ

ベンジンガ・グローバル

Eli Lilly Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

People Also Watch

People Also Watch

Eli Lilly and Co

Eli Lilly Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

PROCantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PROMorgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

ニュース

パートナーシップ

ベンジンガ・グローバル

Eli Lilly Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

PROCantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PROMorgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

People Also Watch

People Also Watch

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430